LC

Lung Cancer Targets and Therapy

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets, and the best use of preventative and integrated treatment interventions to improve outcomes, survival, and quality of life for cancer patients. Its audience includes clinicians, researchers, and medical oncologists involved in the prevention, diagnosis, and treatment of lung cancer. Topics include epidemiology, detection and screening, cellular research and biomarkers, identification of biotargets and agents with novel mechanisms of action, and optimal clinical use of existing anticancer agents, including combination therapies.

Looking to publish in Lung Cancer Targets and Therapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Oncology
Impact Factor 3.3
Quartile Q2
Open Access Type Hybrid
eISSN 1179-2728
Invitation Only No
Cost Range Open access publication costs may be covered by an institutional open access agreement; specific journal pricing is not stated.

Submission Instructions

Lung Cancer Targets and Therapy accepts the following article types. Click on an article type to view submission instructions.

Reviews

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract must not exceed 300 words.
Manuscript Each major section of the manuscript should have a heading. The manuscript must include 3–6 keywords, an Abbreviations section if applicable, funding and competing interest declarations, and an acknowledgment of AI use where applicable.
References References must follow AMA style. Citations must use sequential superscript Arabic numerals, the reference list must be ordered numerically by first citation, journal names must follow PubMed abbreviations, and references with more than six authors must list the first three followed by et al.
Figures & Tables Figures must be uploaded as separate files rather than pasted into the manuscript, while tables may be included in the manuscript or uploaded separately. Each figure and table must be cited in the text, tables must be editable rather than images, and figure and table legends must include explanatory keys when symbols or formatting indicate significant data.
Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

Invited Reviews

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract must not exceed 300 words. Abstract must be unstructured and presented in one paragraph.
Manuscript Manuscript should use major section headings. Manuscript must include 3–6 keywords and an Abbreviations section if applicable, and any AI use must be acknowledged.
References References must follow American Medical Association (AMA) style. References must be cited sequentially as superscript Arabic numerals, listed numerically in citation order, use PubMed journal abbreviations, list all authors when there are six or fewer, list the first three followed by et al when there are more than six, and include access dates for online material.
Figures & Tables Figures must be uploaded as separate files rather than pasted into the manuscript, while tables may be included in the manuscript or uploaded as separate editable files. Each figure and table must be cited in the text, tables must not be submitted as images, and table legends must be placed above each table.
Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

Original Research Papers

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required. Abstract must not exceed 300 words. Abstract must be structured. Structured abstract must use the headings Purpose, Patients and methods, Results, and Conclusion.
Manuscript Manuscript typically includes Abstract, Introduction, Methods, Results, Discussion, and Conclusion sections. Manuscript must include 3–6 keywords, an Abbreviations section if applicable, declarations of funding and competing interests, and acknowledgment of AI use where applicable.
References References must follow American Medical Association (AMA) style. Citations must be sequential superscript Arabic numerals, references must be listed numerically in citation order, journal names must use PubMed abbreviations, and references with more than six authors must list the first three followed by et al.
Figures & Tables Figures must be uploaded as separate files, while tables may be included in the manuscript or uploaded separately with one file per table. Figures must not be pasted into the manuscript, and tables must be submitted in an editable format rather than as images.
Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

Meta-Analyses

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract must not exceed 300 words. Abstract may be structured or unstructured. If structured, the abstract must use the headings Purpose, Patients and methods, Results, and Conclusion.
Manuscript Major sections of the manuscript should each have a heading. Manuscript must include 3–6 keywords, an Abbreviations section if applicable, declarations of funding and competing interests, and an acknowledgement of any AI use.
References References must follow American Medical Association (AMA) style. Citations must use sequential superscript Arabic numerals and the reference list must be numbered in citation order, abbreviate journal names according to PubMed, list all authors when there are six or fewer, list the first three followed by et al when there are more than six, and include access dates for online material.
Figures & Tables Figures must be uploaded as separate files rather than pasted into the manuscript, while tables may be included in the manuscript or uploaded separately as one file per table. Each figure and table must be cited in the text, tables must be editable and not submitted as images, and legends must appear above tables and in figure legends with keys or explanatory notes when needed.
Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

Case Reports

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract must not exceed 300 words. Abstract must be unstructured and presented in one paragraph.
Manuscript Case Report must describe a single patient case. Manuscript must include 3–6 keywords, an Abbreviations section if applicable, and acknowledgment of AI use if applicable.
References References must follow American Medical Association (AMA) style. References must be cited sequentially as superscript Arabic numerals, listed numerically in citation order, use PubMed journal abbreviations, list all authors when there are six or fewer, list the first three followed by "et al." when there are more than six, and include access dates for online material.
Figures & Tables Figures must be uploaded separately from the manuscript, while tables may be included in the manuscript or uploaded as separate files. Figures must be supplied as separate high-quality .jpg, .tif, or .pdf files and not pasted into the manuscript, and tables must be editable and not submitted as images.
Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

Recent Publications

Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer

Si-Yang Liu, Zhi Xie, Lixu Yan, Guang-Ling Jie, Jia-Yi Deng, Qingling Zhang, Zhan Huang, Jin Wang, Zhou Zhang, Yang Shao, Hao Meng, Yan Zhang, Xu-Chao Zhang, Hua-Jun Chen, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

10.2147/lctt.s596080
View Publication

HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report

Misako Nagasaka, Zhaohui Arter, Cathleen Park, Akshat Sarkari, Sai-Hong Ou

10.2147/lctt.s600499
View Publication

Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report

Chunyu Tian, Yang Zou, Jinxin Liu, Jing Zhao, Simiao Tian, Ying Liu, Gang Wang

10.2147/lctt.s605845
View Publication

Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access Challenges

Kim Abbegail Aldecoa, Zhaohui Liao Arter, Sai-Hong Ignatius Ou, Misako Nagasaka

10.2147/lctt.s592922
View Publication

Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients

Putthapoom Lumjiaktase, Nanthisa Kemawichanurat, Kanthon Santiwiwas, Thatchathum Kuttiyod, Songporn Oranratnachai, Narumol Trachu, Nanamon Monnamo, Khantong Khiewngam, Kantapat Simmalee, Thanyanan Reungwetwattana

10.2147/lctt.s578622
View Publication

Frequently asked questions

How long does it take to publish?

Authors must submit proof corrections within 72 hours.

Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

Is a cover letter required?

A point-by-point covering letter is required when submitting a revised manuscript after editorial review.

Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

What are the publication costs?

Open access publication costs may be covered by an institutional open access agreement; specific journal pricing is not stated.

Reformat to Lung Cancer Targets and Therapy using Livewrite Premium

Research Topics

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Lung Cancer Diagnosis and Treatment Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Cancer therapeutics and mechanisms HER2/EGFR in Cancer Research Cancer-related Molecular Pathways Neuroendocrine Tumor Research Advances Cholangiocarcinoma and Gallbladder Cancer Studies Occupational and environmental lung diseases Cancer Mechanisms and Therapy Hepatocellular Carcinoma Treatment and Prognosis Pleural and Pulmonary Diseases Radiomics and Machine Learning in Medical Imaging Advanced Radiotherapy Techniques Gastric Cancer Management and Outcomes Inflammatory Biomarkers in Disease Prognosis Genetic factors in colorectal cancer Peptidase Inhibition and Analysis Cancer survivorship and care Lymphoma Diagnosis and Treatment Epigenetics and DNA Methylation Cancer, Hypoxia, and Metabolism

Related Journals

OA
OncoTargets and Therapy Dove Medical Press
CR
Cancer Research Communications American Association for Cancer Research
JO
Journal of the National Cancer Center Elsevier BV
OR
Oncology Reviews PAGEPress (Italy)
FO
Frontiers of Medicine Higher Education Press
JO
Journal of Chemotherapy Taylor & Francis